News

Dr. Sud Agarwal Leads iNGENu CRO in Launching Groundbreaking Clinical Trials for Sleep Disorders Following Ethics Approval

ingen-cro-logo

iNGENū CRO, a specialist Contract Research Organization with deep expertise in the complex field of sleep medicine, is pleased to announce that two clinical trials targeting rare and debilitating sleep disorders—Idiopathic Hypersomnia and Narcolepsy—have received ethics approval and are now actively enrolling patients. These pivotal studies are being spearheaded by Dr. Sud Agarwal, Specialist Anaesthesiologist […]

continue reading

Reducing Clinical Trial Costs: How iNGENū CRO Helps Startups Bring Treatments to Market Faster

AA1x2YyR

In the world of drug development, the timing and design of clinical trials can be crucial in getting a new drug to market ahead of competition. iNGENū is a leader in helping small and emerging drugmakers design and implement trial plans that maximize both efficiency and cost savings. Thanks to the favorable research environment in […]

continue reading

Pioneering FDA-Compliant Decentralized Trials In Asia-Pacific: iNGENū CRO Leads The Way

ingenu

While DCTs are gaining significant traction in the USA and parts of the EU, no Contract Research Organization (CRO) has successfully scaled decentralised clinical trials across the Asia-Pacific region—until now. iNGENū is the first Asia-Pacific CRO to deliver FDA-focused decentralised clinical trials (DCTs) compliant with 21 CFR 312.120 while leveraging the distinct regulatory and legislative […]

continue reading

Dr. Sud Agarwal’s Predictions for Industry-Sponsored Research in 2025

Dr-3

The life sciences industry is entering 2025 in an environment of heightened financial pressure, geopolitical shifts, and evolving regulatory landscapes. As the CEO of a CRO deeply engaged in global clinical research, Dr. Sud observed several key trends that will shape industry-sponsored research this year. From funding constraints in biotech to rising patient costs and […]

continue reading

Dr. Sud Agarwal and Darryl Davies on IRX211 – A Breakthrough in Managing Breakthrough Cancer Pain (BTcP)


Dr.-Sud

Introduction Breakthrough cancer pain (BTcP) is a sudden and severe pain episode that interrupts the background pain relief provided by long-acting analgesics. Historically, immediate-acting fentanyl-based drugs such as Abstral or Fentora (fentanyl buccal tablets) and Actiq (fentanyl lozenges) were widely used for BTcP. These treatments demonstrated significant pain relief in clinical trials, but their withdrawal […]

continue reading

Dr. Sud Agarwal

Dr. Sud Agarwal

Home: Melbourne, Australia.  Age: 49.  Birthplace: India.  Profession: Specialist anesthesiologist and clinical research physician.  Organization: INGENU CRO.  Title: CEO.  Pronouns: He/Him/His.  Alma mater: University of Bristol, Royal Melbourne Hospital. What one word would your closest friend use to describe you? Focused.  Moral compass: Following in the footsteps of giants.  How do you define a perfect […]

continue reading